JP2018524339A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018524339A5 JP2018524339A5 JP2017567655A JP2017567655A JP2018524339A5 JP 2018524339 A5 JP2018524339 A5 JP 2018524339A5 JP 2017567655 A JP2017567655 A JP 2017567655A JP 2017567655 A JP2017567655 A JP 2017567655A JP 2018524339 A5 JP2018524339 A5 JP 2018524339A5
- Authority
- JP
- Japan
- Prior art keywords
- ring
- alkyl
- compound
- optionally
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 76
- 125000000217 alkyl group Chemical group 0.000 claims description 62
- 125000003118 aryl group Chemical group 0.000 claims description 31
- 125000005843 halogen group Chemical group 0.000 claims description 29
- 125000001424 substituent group Chemical group 0.000 claims description 29
- 229910052739 hydrogen Inorganic materials 0.000 claims description 25
- 125000001153 fluoro group Chemical group F* 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 21
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 125000005842 heteroatoms Chemical group 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 150000002829 nitrogen Chemical group 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 201000008827 tuberculosis Diseases 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 7
- 125000005647 linker group Chemical group 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000003003 spiro group Chemical group 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims description 5
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 229940072185 DRUGS FOR TREATMENT OF TUBERCULOSIS Drugs 0.000 claims description 4
- 125000004429 atoms Chemical group 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229920000728 polyester Polymers 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 125000003368 amide group Chemical group 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- 125000002837 carbocyclic group Chemical group 0.000 claims description 2
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 2
- 125000003262 carboxylic acid ester group Chemical class [H]C([H])([*:2])OC(=O)C([H])([H])[*:1] 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000002346 iodo group Chemical group I* 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 125000004957 naphthylene group Chemical group 0.000 claims description 2
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 230000001808 coupling Effects 0.000 claims 2
- 238000010168 coupling process Methods 0.000 claims 2
- -1 when X b is N Chemical compound 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 0 C*(CC(C)(C1)**1I)*IN* Chemical compound C*(CC(C)(C1)**1I)*IN* 0.000 description 3
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 description 1
- 206010060945 Bacterial infection Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021194493A JP2022043078A (ja) | 2015-07-02 | 2021-11-30 | 抗菌化合物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15174936 | 2015-07-02 | ||
| EP15174936.3 | 2015-07-02 | ||
| EP16174718.3 | 2016-06-16 | ||
| EP16174718 | 2016-06-16 | ||
| EP16174713.4 | 2016-06-16 | ||
| EP16174713 | 2016-06-16 | ||
| PCT/EP2016/065499 WO2017001660A1 (en) | 2015-07-02 | 2016-07-01 | Antibacterial compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021194493A Division JP2022043078A (ja) | 2015-07-02 | 2021-11-30 | 抗菌化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018524339A JP2018524339A (ja) | 2018-08-30 |
| JP2018524339A5 true JP2018524339A5 (US20080131398A1-20080605-C00009.png) | 2019-08-08 |
| JP7099824B2 JP7099824B2 (ja) | 2022-07-12 |
Family
ID=56289523
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017567289A Pending JP2018519302A (ja) | 2015-07-02 | 2016-07-01 | 抗菌化合物 |
| JP2017567655A Active JP7099824B2 (ja) | 2015-07-02 | 2016-07-01 | 抗菌化合物 |
| JP2021194493A Pending JP2022043078A (ja) | 2015-07-02 | 2021-11-30 | 抗菌化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017567289A Pending JP2018519302A (ja) | 2015-07-02 | 2016-07-01 | 抗菌化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021194493A Pending JP2022043078A (ja) | 2015-07-02 | 2021-11-30 | 抗菌化合物 |
Country Status (27)
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA40532A (fr) | 2014-08-28 | 2021-04-28 | Asceneuron Sa | Inhibiteurs de glycosidases |
| SI3316969T1 (sl) | 2015-07-02 | 2022-05-31 | Janssen Sciences Ireland Unlimited Company | Antibakterijske spojine |
| WO2017004500A1 (en) | 2015-07-02 | 2017-01-05 | Genentech, Inc. | Bicyclic lactams and methods of use thereof |
| IL257743B (en) | 2015-09-17 | 2022-08-01 | Marvin J Miller | Heterocyclic compounds containing benzyl amine and preparations useful against mycobacterial inflammation |
| EP3419971B1 (en) | 2016-02-25 | 2022-04-20 | Asceneuron SA | Glycosidase inhibitors |
| SG11201807012QA (en) | 2016-02-25 | 2018-09-27 | Asceneuron S A | Acid addition salts of piperazine derivatives |
| US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| AU2017222964B2 (en) | 2016-02-25 | 2020-01-02 | Asceneuron S. A. | Glycosidase inhibitors |
| ES2947636T3 (es) | 2016-03-16 | 2023-08-14 | Kura Oncology Inc | Derivados de tieno[2,3-d]pirimidina sustituida como inhibidores de menina-MLL y métodos de uso |
| MA45377A (fr) | 2016-06-16 | 2019-04-24 | Janssen Sciences Ireland Unlimited Co | Composés hétérocycliques en tant qu'agents antibacteriens |
| JP7349359B2 (ja) | 2016-10-17 | 2023-09-22 | エフ． ホフマン－ラ ロシュ アーゲー | 二環式ピリドンラクタム及びその使用方法。 |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| AU2018216040A1 (en) | 2017-02-06 | 2019-06-20 | Janssen Pharmaceutica Nv | OGA inhibitor compounds |
| KR20190121315A (ko) | 2017-03-01 | 2019-10-25 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 병용 요법 |
| WO2019037860A1 (en) | 2017-08-24 | 2019-02-28 | Asceneuron S.A. | LINEAR INHIBITORS OF GLYCOSIDASE |
| EP3684361A4 (en) * | 2017-09-20 | 2021-09-08 | Kura Oncology, Inc. | MENINE-MLL SUBSTITUTE INHIBITORS AND METHODS OF USE |
| AU2018352828A1 (en) | 2017-10-17 | 2020-04-23 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| EP3732163A4 (en) | 2017-12-20 | 2021-07-14 | Vanderbilt University | MUSCARINIAN ACETYLCHOLINE RECEPTOR ANTAGONISTS M4 |
| RU2680972C1 (ru) * | 2018-02-13 | 2019-03-01 | Федеральное государственное бюджетное научное учреждение "Центральный научно-исследовательский институт туберкулеза" | Способ определения длительности химиотерапии туберкулеза органов дыхания с множественной и широкой лекарственной устойчивостью МБТ у детей и подростков |
| WO2019175737A1 (en) * | 2018-03-12 | 2019-09-19 | University Of Notre Dame Du Lac | Deuterated imidazopyridines |
| WO2019204537A1 (en) | 2018-04-20 | 2019-10-24 | Genentech, Inc. | N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
| WO2020039029A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Spiro compounds as glycosidase inhibitors |
| US12016852B2 (en) | 2018-08-22 | 2024-06-25 | Asceneuron Sa | Pyrrolidine glycosidase inhibitors |
| WO2020039028A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Tetrahydro-benzoazepine glycosidase inhibitors |
| CN109503631A (zh) * | 2018-12-29 | 2019-03-22 | 中国医学科学院医药生物技术研究所 | 含有二氮杂螺环片段的咪唑并[1,2-a]吡啶-3-酰胺类化合物及其制备方法和应用 |
| EP3976031A4 (en) * | 2019-05-28 | 2023-07-12 | Shionogi & Co., Ltd | MEDICATION FOR THE TREATMENT OF MYCOBACTERIAL INFECTION IN THE FORM OF A COMBINATION OF A CYTOCHROME BC1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMIN |
| KR102076958B1 (ko) | 2019-06-24 | 2020-02-13 | 엘티소재주식회사 | 헤테로고리 화합물 및 이를 이용한 유기 발광 소자 |
| TW202124379A (zh) | 2019-09-10 | 2021-07-01 | 日商鹽野義製藥股份有限公司 | 對分枝桿菌感染有用之含苄胺的５，６－雜芳族化合物 |
| JP2022548247A (ja) | 2019-09-13 | 2022-11-17 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | 抗菌化合物 |
| CA3149988A1 (en) | 2019-09-30 | 2021-04-08 | Jerome Emile Georges Guillemont | 4-QUINOLINONE ANTIBACTERIAL COMPOUNDS |
| BR112022005449A2 (pt) | 2019-09-30 | 2022-06-21 | Janssen Sciences Ireland Unlimited Co | Compostos antibacterianos |
| KR20220122649A (ko) | 2019-12-27 | 2022-09-02 | 테크니메데 소시에다데 테크니코-메디시날 에스.에이. | 신규한 약학 조성물(new pharmaceutical compounds) |
| EP4308239A1 (en) | 2021-03-16 | 2024-01-24 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| KR20230158046A (ko) | 2021-03-17 | 2023-11-17 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 항박테리아성 화합물 |
| CA3212074A1 (en) | 2021-03-17 | 2022-09-22 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2022214520A1 (en) | 2021-04-07 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2022214519A1 (en) | 2021-04-07 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2023275744A1 (en) | 2021-06-29 | 2023-01-05 | TECNIMEDE - Sociedade Técnico-medicinal, SA | Heterocyclic compounds for the treatment of tuberculosis |
| CN118159543A (zh) | 2021-10-28 | 2024-06-07 | 爱尔兰詹森科学公司 | 在治疗细菌感染中使用的咪唑并吡啶酰胺和相关化合物 |
| WO2023244764A1 (en) * | 2022-06-15 | 2023-12-21 | C4 Therapeutics, Inc. | Compounds for the targeted degradation of smarca2 |
| WO2024089170A1 (en) | 2022-10-27 | 2024-05-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100392216B1 (ko) | 1994-11-15 | 2003-10-17 | 파마시아 앤드 업존 캄파니 | 이환상옥사진및티아진옥사졸리디논항세균물질 |
| ATE204874T1 (de) | 1995-05-11 | 2001-09-15 | Upjohn Co | Spirocyclische und bicyclische diazinyl- und carbazinyloxazolidinone |
| DE60332023D1 (de) | 2002-07-25 | 2010-05-20 | Janssen Pharmaceutica Nv | Chinolinderivate und deren verwendung als mycobakterielle inhibitoren |
| AR042956A1 (es) | 2003-01-31 | 2005-07-13 | Vertex Pharma | Inhibidores de girasa y usos de los mismos |
| MA27360A1 (fr) | 2004-11-23 | 2005-06-01 | Brahim Bennani | Synthese et application des spiro-isoxazolines comme agents anti-tuberculeux |
| WO2008082490A2 (en) | 2006-12-20 | 2008-07-10 | Schering Corporation | Novel jnk inhibitors |
| TW200901969A (en) * | 2007-06-06 | 2009-01-16 | Smithkline Beecham Corp | Chemical compounds |
| TWI498115B (zh) | 2007-12-27 | 2015-09-01 | Daiichi Sankyo Co Ltd | 咪唑羰基化合物 |
| CA2712613C (en) | 2008-03-26 | 2017-02-28 | Global Alliance For Tb Drug Development | Bicyclic nitroimidazoles covalently linked to substituted phenyl oxazolidinones |
| CA2732750A1 (en) | 2008-09-22 | 2010-03-25 | The Government Of The United States Of America D.B.A.The Department Of V Eterans Affairs | Methods for detecting a mycobacterium tuberculosis infection |
| CA2748274A1 (en) | 2008-12-30 | 2010-07-08 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as raf kinase inhibitors |
| US9309238B2 (en) | 2009-11-05 | 2016-04-12 | University Of Notre Dame Du Lac | Imidazo [1,2-a]pyridine compounds, synthesis thereof, and methods of using same |
| SG184073A1 (en) | 2010-03-18 | 2012-10-30 | Pasteur Institut Korea | Anti-infective compounds |
| WO2012143796A2 (en) | 2011-04-21 | 2012-10-26 | Institut Pasteur Korea | Anti-inflammation compounds |
| CA2845785A1 (en) | 2011-09-01 | 2013-03-07 | Irm Llc | Compounds and compositions as c-kit kinase inhibitors |
| US9199981B2 (en) | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
| EP2751104B1 (en) | 2011-09-01 | 2019-09-25 | Novartis AG | Compounds and compositions as c-kit kinase inhibitors |
| PT2820008T (pt) * | 2012-03-02 | 2017-05-05 | Genentech Inc | Amidas amido-espirocíclicas e derivados de sulfonamidas |
| KR101918469B1 (ko) | 2012-06-04 | 2018-11-15 | 한국화학연구원 | 바이사이클릭 니트로이미다졸 유도체 또는 이들의 광학이성질체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물 |
| AU2013292529A1 (en) * | 2012-07-18 | 2015-02-12 | Marvin J. Miller | 5,5-heteroaromatic anti-infective compounds |
| KR101650716B1 (ko) | 2012-11-22 | 2016-08-24 | 한국화학연구원 | 바이시클릭니트로이미다졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 결핵의 예방 또는 치료용 약학적 조성물 |
| EP3027615B1 (en) * | 2013-08-02 | 2021-07-21 | Institut Pasteur Korea | Anti-infective compounds |
| KR101564425B1 (ko) | 2013-11-26 | 2015-10-30 | 한국화학연구원 | 신규한 바이사이클릭 니트로이미다졸 카바메이트 화합물, 이를 제조하는 방법 및 이를 유효성분으로 함유하는 결핵 질환의 예방 또는 치료용 약제학적 조성물 |
| CN105524058B (zh) * | 2014-10-21 | 2018-03-27 | 广州艾格生物科技有限公司 | 吡唑并[1,5‑a]吡啶类化合物及其应用 |
| US10080749B2 (en) | 2014-11-03 | 2018-09-25 | The Regents Of The University Of California | Multi-drug therapies for tuberculosis treatment |
| SI3316969T1 (sl) * | 2015-07-02 | 2022-05-31 | Janssen Sciences Ireland Unlimited Company | Antibakterijske spojine |
| MA45377A (fr) | 2016-06-16 | 2019-04-24 | Janssen Sciences Ireland Unlimited Co | Composés hétérocycliques en tant qu'agents antibacteriens |
| AU2017286370B2 (en) | 2016-06-16 | 2021-09-09 | Janssen Sciences Ireland Uc | Heterocyclic compounds as antibacte rials |
| KR20190121315A (ko) | 2017-03-01 | 2019-10-25 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 병용 요법 |
-
2016
- 2016-07-01 SI SI201631501T patent/SI3316969T1/sl unknown
- 2016-07-01 WO PCT/EP2016/065503 patent/WO2017001661A1/en active Application Filing
- 2016-07-01 ES ES16734637T patent/ES2914681T3/es active Active
- 2016-07-01 US US15/736,375 patent/US10364232B2/en active Active
- 2016-07-01 CA CA2986326A patent/CA2986326A1/en active Pending
- 2016-07-01 AU AU2016287477A patent/AU2016287477B2/en active Active
- 2016-07-01 CA CA2986331A patent/CA2986331A1/en not_active Abandoned
- 2016-07-01 RS RS20220464A patent/RS63201B1/sr unknown
- 2016-07-01 AU AU2016287478A patent/AU2016287478B2/en not_active Expired - Fee Related
- 2016-07-01 MX MX2017016789A patent/MX2017016789A/es unknown
- 2016-07-01 CN CN202111173668.2A patent/CN113980015A/zh active Pending
- 2016-07-01 WO PCT/EP2016/065499 patent/WO2017001660A1/en active Application Filing
- 2016-07-01 EA EA201890201A patent/EA201890201A1/ru unknown
- 2016-07-01 EP EP22158386.7A patent/EP4074378A1/en active Pending
- 2016-07-01 HR HRP20220339TT patent/HRP20220339T1/hr unknown
- 2016-07-01 PE PE2017002738A patent/PE20180520A1/es unknown
- 2016-07-01 UA UAA201800904A patent/UA125171C2/uk unknown
- 2016-07-01 US US15/736,524 patent/US20180155341A1/en not_active Abandoned
- 2016-07-01 MX MX2017016788A patent/MX2017016788A/es unknown
- 2016-07-01 JP JP2017567289A patent/JP2018519302A/ja active Pending
- 2016-07-01 PL PL16734637T patent/PL3316969T3/pl unknown
- 2016-07-01 CN CN201680038644.7A patent/CN108235704B/zh active Active
- 2016-07-01 KR KR1020187001923A patent/KR20180022826A/ko not_active Application Discontinuation
- 2016-07-01 KR KR1020187002072A patent/KR20180022833A/ko not_active Application Discontinuation
- 2016-07-01 BR BR112017028318-2A patent/BR112017028318B1/pt active IP Right Grant
- 2016-07-01 LT LTEPPCT/EP2016/065499T patent/LT3316969T/lt unknown
- 2016-07-01 EP EP16733105.7A patent/EP3316968A1/en not_active Ceased
- 2016-07-01 EP EP16734637.8A patent/EP3316969B1/en active Active
- 2016-07-01 MA MA042293A patent/MA42293A/fr unknown
- 2016-07-01 JP JP2017567655A patent/JP7099824B2/ja active Active
- 2016-07-01 CN CN201680038659.3A patent/CN107708809A/zh active Pending
- 2016-07-01 MD MDE20180478T patent/MD3316969T2/ro unknown
- 2016-07-01 EA EA201890204A patent/EA201890204A1/ru unknown
- 2016-07-01 DK DK16734637.8T patent/DK3316969T3/da active
-
2017
- 2017-12-13 PH PH12017502298A patent/PH12017502298B1/en unknown
- 2017-12-13 PH PH12017502297A patent/PH12017502297A1/en unknown
- 2017-12-18 IL IL256391A patent/IL256391B/en active IP Right Grant
- 2017-12-18 IL IL256379A patent/IL256379A/en unknown
- 2017-12-26 CO CONC2017/0013408A patent/CO2017013408A2/es unknown
- 2017-12-27 CL CL2017003404A patent/CL2017003404A1/es unknown
-
2018
- 2018-07-13 HK HK18109081.1A patent/HK1249468A1/zh unknown
- 2018-10-25 HK HK18113658.6A patent/HK1254677A1/zh unknown
-
2019
- 2019-07-02 US US16/460,334 patent/US20190330189A1/en not_active Abandoned
-
2020
- 2020-04-14 US US16/848,337 patent/US11180472B2/en active Active
-
2021
- 2021-09-17 US US17/477,970 patent/US11866419B2/en active Active
- 2021-11-30 JP JP2021194493A patent/JP2022043078A/ja active Pending
-
2022
- 2022-01-20 AU AU2022200385A patent/AU2022200385B2/en active Active
-
2023
- 2023-11-29 US US18/523,171 patent/US20240132470A1/en active Pending
